Trial: 202102009

A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation



Principal Investigator

Govindan, Ramaswamy

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Metastatic Disease; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: